Navigation Links
Provenance Biopharmaceuticals Corp. Announces $8M Financing Arrangement
Date:12/22/2011

WALTHAM, Mass., Dec. 22, 2011 /PRNewswire/ -- Provenance Biopharmaceuticals Corp. ("Provenance") announced today the closing of an $8 million financing arrangement with Alopexx Enterprises, LLC for the continued development of anti-cancer therapeutic, DI-Leu16-IL2.

DI-Leu16-IL2 is among a class of molecules called immunocytokines that are being developed for the treatment of various forms of cancer.  Immunocytokines, combine the immune stimulating features of cytokines with the targeting properties of antibodies. DI-Leu16-IL2, Provenance's most advanced program, is a de-immunized form of an anti-CD20 antibody, Leu16, genetically fused to the cytokine, interleukin 2 (IL2). DI-Leu16-IL2 is being studied for the treatment of non-Hodgkin's lymphoma and other forms of hematological cancer and is currently in an investigator sponsored Phase I clinical trial.

Under the terms of the financing, Provenance and Alopexx Enterprises, LLC have formed a new company, Alopexx Oncology, LLC to manage the clinical development of DI-Leu16-IL2. Financial details of the transaction are not disclosed.

About Provenance Biopharmaceuticals Corp.

Provenance is a clinical-stage biotechnology company focused on developing novel therapeutics for cancer and other serious, life-threatening diseases. The Company's engineered antibody technologies promote the body's own immune system to recognize and fight disease. In addition to DI-Leu16-IL2, Provenance has several additional early-stage molecules in development. For more information, please go to http://www.provenancebio.com.

About Alopexx Enterprises, LLC.

Alopexx Enterprises, LLC is a healthcare company focused on acquiring and developing preclinical and early clinical compounds, with an emphasis on infectious diseases, oncology, and CNS.  It was founded in 2011 by highly experienced pharmaceutical executives and leverages the unique insights and experiences of its founders and world-class scientific advisors. Beyond the financial investment the group is able to offer hands-on expertise in pre-clinical development, manufacturing, regulatory affairs, logistics, clinical development and partnering.  For more information please go to www.alopexx.com.


'/>"/>
SOURCE Provenance Biopharmaceuticals Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires
2. Keryx Biopharmaceuticals Announces Phase 2 Data for KRX-0401 (Perifosine) in Hodgkins Lymphoma Presented at ASH Meeting
3. Inspiration Biopharmaceuticals Presents Key Scientific Data from its Two Lead Hemophilia Development Programs at the 53rd Annual Meeting of the American Society of Hematology (ASH)
4. Inspiration Biopharmaceuticals Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1
5. Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Keryx Biopharmaceuticals to Present at Lazard Capital Markets 8th Annual Healthcare Conference
7. Planet Biopharmaceuticals, Inc. Divests Assets of Allergy Control Products, Inc.
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Third Quarter 2011 Financial Results
10. Inspiration Biopharmaceuticals Names John P. Butler Chief Executive Officer
11. CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on Provistaco.com ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris F. ... AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking place ... the field of medical informatics, this prestigious award is presented to an individual whose ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
Breaking Medicine News(10 mins):